Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER		PATIENT:
Name:		Name:
Ward:		NHI:
Dexrazoxan	e	
O Prese	(tick boxes where appropriate) cribed by, or recommended by a medical oncologist, paediatric stocol or guideline that has been endorsed by the Te Whatu Ora	oncologist, haematologist or paediatric haematologist, or in accordance with Hospital.
and and	Patient is to receive treatment with high dose anthracycline given Based on current treatment plan, patient's cumulative lifetime greater Dexrazoxane to be administered only whilst on anthracycline to	dose of anthracycline will exceed 250mg/m2 doxorubicin equivalent or
or	O Treatment to be used as a cardioprotectant for a child or O Treatment to be used as a cardioprotectant for secondar	

C:	D-1	
Signed.	Date:	
Oigilica.	 Daic.	